Application of STAT1 / 3 inhibitor in preparation of medicine for improving cis-platinum drug resistance
Patent Information
- Application Number
- CN202310586200.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-23
- Publication Date
- 2024-11-26
AI Technical Summary
Cisplatin anticancer drugs are prone to drug resistance and toxic side effects in long-term treatment. The prior art has failed to effectively use STAT1/3 inhibitors to regulate their repair of DNA damage to improve their efficacy.
A STAT1/3 inhibitor, including nifuzid, was designed in combination with cisplatin, by targeting STAT1 and STAT3 proteins, reducing its activity, combining small molecule inhibitors CBL0137 and Nifuroxazide with cisplatin, enhancing Sensitivity to drug-resistant cells.
It significantly enhances the killing effect of cisplatin on drug-resistant non-small cell lung cancer cells, provides a new idea to overcome tumor drug resistance, especially for the treatment of cisplatin-resistant lung cancer and non-small cell lung cancer.
Smart Images

Figure CN119015271A_ABST
Abstract
Citation Information
Cited By
Small molecule compound CBL0137 for treating skin T cell lymphoma and application thereof
CN121081461A
